The current financial score of Oragenics Inc is 6.79. Its financial status is robust, and its operating efficiency is low.
The current valuation score of Oragenics Inc is 8.78. Its current P/E ratio is -0.37, which is -89.38% below the recent high of -0.04 and -1249.11% above the recent low of -4.93.
No earnings forecast score is currently available for Oragenics Inc. The Biotechnology & Medical Research industry's average is 8.11. The average price target is 2.00, with a high of 2.00 and a low of 2.00.
The current price momentum score of Oragenics Inc is 3.46. Currently, the stock price is trading between the resistance level at 0.55 and the support level at 0.48, making it suitable for range-bound swing trading.
The current institutional shareholding score of Oragenics Inc is 3.00. The latest institutional shareholding proportion is 8.15%, representing a quarter-over-quarter decrease of 38.79%.
The current risk assessment score of Oragenics Inc is 3.33. The company's beta value is 1.27. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.